Redwire announced that it has successfully 3D bioprinted the first live human heart tissue sample though its 3D BioFabrication Facility BFF onboard the International Space Station ISS . The tissue sample returned to Earth along with the second batch of pharmaceutical crystal experiments from Redwire’s PIL-BOX platform…”These are extraordinary scientific achievements that bring us closer to reliable, large-scale commercial biotech services on-orbit,” said Redwire In-Space Industries President John Vellinger. “With BFF and PIL-BOX, Redwire has leveraged decades of spaceflight heritage to position itself as a market leader for space biotech capabilities and is now setting the pace for on-orbit contract development and production.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDW:
- Redwire awarded study contract for DMA 3 of NASA’s Mars program
- Redwire in MOU to support Boryung’s Humans In Space program
- Redwire Corporation Braces for Impact: Economic Uncertainty and Potential Recession Threaten Financial Stability
- Redwire: Lilly investigation yields ‘exciting’ results for drug discovery
- Redwire price target raised to $6 from $5 at Alliance Global Partners